Study guide

8.2 Psychosis, Schizophrenia & Acute Agitation

Professional and Linguistic Assessments Board Part 1 PLAB 1

Track your progress as you read

Finished sections get a check mark.

1 Introduction

About the PLAB 1 Exam

2 Chapter 1: Acute Medicine, Resuscitation & Clinical Emergencies

1.1 The ABCDE Approach, Adult Resuscitation & Shock 1.2 Sepsis, Sepsis Six Protocol & Septic Shock 1.3 Anaphylaxis & Acute Airway Emergencies 1.4 Clinical Toxicology & Acute Poisoning 1.5 Major Trauma, Head Injury, Burns & Environmental Emergencies

3 Chapter 2: Cardiovascular Medicine & Vascular Disorders

2.1 Acute Coronary Syndromes (STEMI & NSTEMI/Unstable Angina) 2.2 Heart Failure & Cardiogenic Shock 2.3 Cardiac Arrhythmias & Syncope 2.4 Hypertension, Valvular Heart Disease & Aortic Emergencies 2.5 Infective Endocarditis, Pericardial Disease, Myocarditis & Cardiomyopathies 2.6 Peripheral Arterial Disease, Aortic Aneurysm & Venous Disease

4 Chapter 3: Respiratory Medicine

3.1 Asthma: Diagnostic Criteria, Chronic Stepping & Acute Exacerbations 3.2 COPD: Staging, Long-Term Management & Acute Exacerbations 3.3 Pneumonia & Lower Respiratory Tract Infections 3.4 Venous Thromboembolism, Pleural Disease & Pneumothorax 3.5 Lung Cancer, Interstitial & Suppurative Lung Disease, Sleep Apnoea & Respiratory Failure

5 Chapter 4: Gastroenterology, Hepatobiliary & General Surgery

4.1 Upper Gastrointestinal Bleeding & Dyspepsia 4.2 Lower Gastrointestinal Bleeding, IBD & Colorectal Malignancy 4.3 Acute Abdomen, Bowel Obstruction & Perforation 4.4 Hepatobiliary Disease, Cirrhosis & Acute Pancreatitis 4.5 Functional, Malabsorptive & Infective Bowel Disorders, Anorectal Disease, Hernias & MASLD

6 Chapter 5: Renal Medicine, Urology & Fluid/Electrolyte Balance

5.1 Acute Kidney Injury & KDIGO Staging 5.2 Chronic Kidney Disease & Glomerular Disorders 5.3 Electrolyte Emergencies: Potassium, Sodium & Calcium 5.4 Urology: Urinary Tract Infections, Renal Colic & Urinary Retention 5.5 Urological Cancers, Prostate Disease & Scrotal Emergencies

7 Chapter 6: Endocrinology & Metabolic Medicine

6.1 Diabetes Mellitus: Diagnostic Criteria & Chronic Management 6.2 Diabetic Emergencies: DKA & Hyperosmolar Hyperglycaemic State 6.3 Thyroid Disorders: Hypothyroidism, Thyrotoxicosis & Thyroid Storm 6.4 Adrenal & Pituitary Disorders: Addisonian Crisis & Pituitary Disease

8 Chapter 7: Neurology & Neurosciences

7.1 Acute Stroke, TIA & Intracranial Haemorrhage 7.2 Acute & Chronic Headaches, Giant Cell Arteritis & CNS Infections 7.3 Seizures, Status Epilepticus & Epilepsy Management 7.4 Neuromuscular Disorders & Movement Disorders 7.5 Raised Intracranial Pressure, Brain Tumours, Cranial Nerve Lesions & Spinal Cord Disorders

9 Chapter 8: Psychiatry & Mental Health

8.1 Affective Disorders: Depression, Bipolar Disorder & Suicide Risk Assessment 8.2 Psychosis, Schizophrenia & Acute Agitation 8.3 Cognitive Disorders, Substance Misuse & the Mental Health Act 8.4 Anxiety Disorders, OCD, PTSD, Eating Disorders, Personality Disorders & Somatic Presentations 8.5 Perinatal, Child & Adolescent and Neurodevelopmental Mental Health

10 Chapter 9: Obstetrics, Gynaecology & Sexual Health

9.1 Early Pregnancy: Miscarriage & Ectopic Pregnancy 9.2 Antenatal & Peripartum Emergencies: Pre-Eclampsia & Haemorrhage 9.3 Common Gynaecological Presentations & Gynaecological Oncology 9.4 Contraception, Emergency Contraception & Sexually Transmitted Infections 9.5 Routine Antenatal Care, Labour & Obstetric Emergencies 9.6 Menopause & HRT, Subfertility, Prolapse & Urinary Incontinence

11 Chapter 10: Paediatrics & Child Health

10.1 The Febrile Child, Sepsis & Meningococcal Disease 10.2 Paediatric Respiratory Distress: Croup, Bronchiolitis & Wheeze 10.3 Paediatric Abdominal Emergencies, Dehydration & Neonatal Jaundice 10.4 Child Safeguarding, Non-Accidental Injury & Developmental Milestones 10.5 Neonatology & Congenital Heart Disease 10.6 Paediatric Orthopaedics, Growth, Childhood Cancer & Common Chronic Problems

12 Chapter 11: Musculoskeletal Medicine & Rheumatology

11.1 Inflammatory Arthropathies & Connective Tissue Diseases 11.2 Crystal Arthropathies (Gout & Pseudogout) & Septic Arthritis 11.3 Osteoporosis, Common Fractures & Orthopaedic Emergencies 11.4 Osteoarthritis, Low Back Pain, Polymyalgia Rheumatica, Fibromyalgia & Soft Tissue Disorders

13 Chapter 12: Dermatology, ENT & Ophthalmology

12.1 Common Dermatoses & Dermatological Emergencies 12.2 ENT Presentations: Infections, Epistaxis, Vertigo, Hearing Loss & Head and Neck Lumps 12.3 The Acute Red Eye: Glaucoma, Uveitis & Keratitis 12.4 Sudden & Gradual Vision Loss, Retinal Disorders & the Visual Pathway 12.5 Skin Infections, Infestations, Childhood Rashes & Skin Cancer

14 Chapter 13: Haematology, Oncology & Palliative Care

13.1 Anaemias & Blood Transfusion Medicine 13.2 Haematological Malignancies: Leukaemias, Lymphomas & Myeloma 13.3 Haemostasis, Coagulation Disorders & Anticoagulant Reversal 13.4 Oncological Emergencies & Palliative Symptom Management 13.5 Breast Disease, Cancer Screening & Suspected Cancer Referral

15 Chapter 14: Perioperative Care, Safe Prescribing & Clinical Pharmacology

14.1 Preoperative Assessment & Perioperative Medication Management 14.2 Postoperative Complications & Fluid Therapy 14.3 High-Risk Medications & Therapeutic Drug Monitoring 14.4 Safe Prescribing Principles & Antimicrobial Stewardship

16 Chapter 15: Medical Ethics, Law & UK Clinical Practice

15.1 GMC Good Medical Practice, Professionalism, Teamwork & Quality Improvement 15.2 Consent, Capacity & the Mental Capacity Act 2005 15.3 Confidentiality, Statutory Reporting & DVLA Regulations 15.4 End-of-Life Decisions, DNACPR, Organ Donation, Adult Safeguarding & Domestic Abuse

17 Chapter 16: Infectious Diseases, Travel Medicine & Infection Prevention

16.1 Tuberculosis, HIV, Hepatitis B & C and Needlestick Injuries 16.2 Fever in the Returning Traveller, Zoonoses, Notifiable Diseases & Infection Prevention

18 Chapter 17: Older Adults, Population Health, Genetics & Clinical Imaging

17.1 Frailty, Falls, Polypharmacy, Continence & Pressure Ulcers 17.2 Medical Statistics, Diagnostic Tests & Critical Appraisal 17.3 Public Health, Screening Principles, Health Inequalities & Health Promotion 17.4 Genetics, Genomics & Pharmacogenomics 17.5 Clinical Imaging: Choosing Tests, Radiation Safety & Interpreting X-rays

8.2 Psychosis, Schizophrenia & Acute Agitation

Key Takeaways Explain This Topic AI

Schizophrenia diagnosis is anchored by Schneiderian first-rank symptoms (third-person auditory hallucinations, running commentary, thought alienation, passivity phenomena) persisting for ≥1 month.

Second-generation antipsychotics are first-line to minimize extrapyramidal side effects, though they necessitate metabolic surveillance for weight gain, dyslipidaemia, and hyperprolactinaemia (notably with risperidone).

Acute dystonic reactions require prompt anticholinergic therapy with procyclidine IM/IV, whereas tardive dyskinesia is worsened by anticholinergics and requires medication review and potential transition to clozapine.

Clozapine is uniquely indicated for treatment-resistant schizophrenia (failure of ≥2 adequate trials) and carries a mandatory hematological monitoring protocol due to the life-threatening risk of agranulocytosis.

Neuroleptic malignant syndrome (NMS) presents with hyperthermia, 'lead-pipe' rigidity, autonomic storm, and marked CK elevation; management requires stopping antipsychotics, aggressive cooling, and bromocriptine or dantrolene.

Last updated: October 2026

Psychosis, Schizophrenia & Acute Agitation

In accordance with NICE clinical guideline CG178 (Psychosis and schizophrenia in adults) , psychotic disorders are characterized by a loss of contact with reality, manifesting through abnormalities in perception, belief, and behavioral organization. Core clinical competencies include recognizing Schneiderian first-rank symptoms, managing antipsychotic adverse effects, adhering to mandatory monitoring registers in treatment resistance, and executing rapid tranquillisation safely.

Clinical Phenomenology of Schizophrenia & First-Rank Symptoms

Under ICD-11 and DSM-5 , schizophrenia requires continuous disturbance for at least 1 month (with functional decline persisting for 6 months under DSM-5). Organic causes (cannabis/stimulant intoxication, anti-NMDA receptor encephalitis, Wilson's disease, SLE, temporal lobe epilepsy) must be rigorously excluded.

Kurt Schneider's First-Rank Symptoms (FRS)

Auditory Hallucinations:

Third-person voices: Voices conversing or arguing about the patient ( "He shouldn't do that" ).

Running commentary: Voices narrating the patient's ongoing actions in real-time.

Thought echo ( Gedankenlautwerden ): The patient hears their own thoughts spoken aloud.

Delusional Perception: A normal real-world sensory perception is instantaneously linked to an abnormal, private delusional meaning (e.g., seeing a green traffic light and knowing one is chosen to lead the nation).

Thought Alienation (Passivity of Thought):

Thought insertion: Unshakeable conviction that alien thoughts are placed into one's mind from outside.

Thought withdrawal: Belief that thoughts are being removed or stolen from one's mind.

Thought broadcast: Belief that thoughts are radiating outwardly and heard by others.

Passivity Phenomena (Delusions of Control):

Experiences where emotions ( made affect ), impulses ( made impulse ), or actions ( made volition ) are controlled by an external force.

Somatic passivity: Bodily sensations experienced as being inflicted by an outside entity.

Positive vs Negative Symptoms

Positive Symptoms (Mesolimbic Hyperdopaminergia): Delusions, hallucinations, and formal thought disorder (tangentiality, derailment, neologisms, word salad).

Negative Symptoms (Mesocortical Hypodopaminergia): The 5 As : Avolition (lack of drive), Anhedonia , Alogia (poverty of speech), Affective flattening (blunted affect), and Asociality (social withdrawal).

Antipsychotic Pharmacotherapy: FGAs vs SGAs

First-Generation Antipsychotics (FGAs e.g., Haloperidol, Chlorpromazine, Flupentixol):

Mechanism: Potent antagonism of dopamine D2 receptors in the mesolimbic tract. High D2 blockade in the nigrostriatal tract causes marked Extrapyramidal Side Effects (EPSEs) ; blockade in the tuberoinfundibular tract causes hyperprolactinaemia .

Second-Generation Antipsychotics (SGAs e.g., Olanzapine, Risperidone, Quetiapine, Aripiprazole):

Mechanism: Dual 5-HT2A and D2 receptor antagonism (Aripiprazole is a partial D2 agonist). Reduced EPSE risk, but substantial metabolic syndrome liability (weight gain, dyslipidaemia, impaired fasting glucose, new-onset type 2 diabetes).

Drug Profiles:

Olanzapine: Highest risk of weight gain and metabolic syndrome (monitor HbA1c, lipids, BMI).

Risperidone: Potent tuberoinfundibular D2 blockade causing pronounced hyperprolactinaemia (galactorrhoea, amenorrhoea, gynaecomastia, sexual dysfunction, osteopenia).

Aripiprazole: Partial D2 agonist; metabolically neutral, weight-neutral, and prolactin-sparing.

Quetiapine: Very low striatal D2 affinity; lowest EPSE risk (preferred in Parkinson's disease psychosis), but sedating.

Extrapyramidal Side Effects (EPSEs): Classification & Management

EPSE Category Clinical Onset Characteristic Signs & Symptoms Pathophysiological Mechanism Clinical Management

Acute Dystonia Hours to days Involuntary sustained painful muscle spasms: oculogyric crisis (upward eye deviation), torticollis (neck torsion), trismus (jaw clench), laryngeal spasm Acute striatal dopamine-acetylcholine imbalance producing relative cholinergic excess Procyclidine 5–10 mg IM or IV (or Benzatropine); provides rapid relief within minutes.

Akathisia Days to weeks Intense subjective inner motor restlessness , inability to sit still, continuous pacing, severe distress Nigrostriatal and mesocortical dopamine blockade Reduce dose; switch to quetiapine/aripiprazole; first-line medical therapy: Propranolol 10–40 mg TDS or low-dose Lorazepam .

Drug-Induced Parkinsonism Weeks to months Triad of tremor (resting pill-rolling), rigidity (cogwheel/lead-pipe), and bradykinesia (festinating gait, masked facies) Nigrostriatal dopamine D2 depletion Reduce dose; switch to SGA; add oral anticholinergic ( Procyclidine 2.5–5 mg TDS ). Avoid indefinite anticholinergics.

Tardive Dyskinesia (TD) Months to years Involuntary choreoathetoid movements: orofacial dyskinesia (lip-smacking, tongue protrusion [ "fly-catcher tongue" ], chewing motions), chorea of limbs Chronic D2 blockade causing striatal dopamine receptor upregulation and supersensitivity Discontinue anticholinergics immediately (anticholinergics worsen TD!). Reduce antipsychotic; switch to Clozapine ; consider VMAT2 inhibitors ( Valbenazine ).

Treatment-Resistant Schizophrenia & Clozapine Protocols

Treatment-Resistant Schizophrenia (TRS): Lack of symptomatic remission despite at least two adequate trials of different antipsychotics (each for ≥6–8 weeks at therapeutic doses), with at least one being an SGA.

Clozapine Indication: The only evidence-based antipsychotic for TRS; uniquely reduces suicide and persistent aggression in schizophrenia.

Caution

Agranulocytosis Risk & FBC Protocol: Clozapine carries a 1% risk of life-threatening agranulocytosis. Mandatory central monitoring (CPMS/ZTAS) requires FBC monitoring: weekly for weeks 1–18 , fortnightly for weeks 19–52 , then monthly thereafter.

Mandatory Stop Rule: Stop clozapine immediately and permanently if Absolute Neutrophil Count (ANC) < 1.5 x 10^9/L OR White Cell Count (WCC) < 3.0 x 10^9/L . Never rechallenge. Admit for protective reverse barrier isolation and IV broad-spectrum antibiotics for neutropenic sepsis.

Other Critical Clozapine Toxicities

Severe Constipation / Paralytic Ileus: Potent anticholinergic/antiserotonergic gut hypomotility; leading cause of clozapine-related death . Prescribe routine prophylactic laxatives (senna, docusate).

Myocarditis & Cardiomyopathy: Most common within first 2 months; monitor troponin, CRP, and baseline echocardiogram. Discontinue if myocarditis develops.

Hypersalivation (Sialorrhoea): Treat with sublingual ipratropium spray or oral hyoscine.

Seizures: Dose-dependent; manage with sodium valproate (avoid carbamazepine due to bone marrow suppression).

Neuroleptic Malignant Syndrome (NMS): Diagnosis & Emergency Management

An idiosyncratic, life-threatening complication of dopamine D2 antagonists (or sudden L-Dopa withdrawal).

  • Cardinal Tetrad & Investigations
  • Severe "Lead-Pipe" Muscle Rigidity
  • Hyperthermia (>38.0°C, often >40°C)
  • Autonomic Instability (profuse sweating, tachycardia, tachypnoea, labile BP)
  • Altered Mental Status (confusion, catatonia, stupor, coma)

Investigations: Marked Creatine Kinase elevation (CK > 1000 IU/L, frequently >10,000–50,000 IU/L) from rhabdomyolysis, leukocytosis (15–30 x 10^9/L), acute renal failure (myoglobinuria), and metabolic acidosis.

Diagnostic Comparison: NMS vs Serotonin Syndrome

Feature Neuroleptic Malignant Syndrome (NMS) Serotonin Syndrome (SS)

Offending Drugs Dopamine D2 antagonists (haloperidol, olanzapine) or L-Dopa withdrawal Serotonergic combinations (SSRI + MAOI, tramadol, linezolid, triptans)

Onset Subacute: days to weeks (typically 3–9 days) Hyperacute: hours (typically 6–24 hours)

Neuromuscular Signs Severe generalized "lead-pipe" rigidity , hyporeflexia Neuromuscular hyperactivity: spontaneous clonus , ocular clonus, hyperreflexia, tremor

Pupils & Bowel Normal pupils; normal or reduced bowel sounds Mydriasis (dilated pupils) ; hyperactive bowel sounds, diarrhoea

Creatine Kinase Massively elevated (>10,000 IU/L) Normal or mildly elevated

Specific Medical Therapy Bromocriptine (dopamine agonist) or Dantrolene (muscle relaxant) Cyproheptadine (5-HT2A antagonist)

Emergency Management Protocol

Stop all antipsychotics immediately; admit to ICU/HDU.

Aggressive IV fluid resuscitation with 0.9% normal saline (maintaining urine output >100–200 mL/h to prevent acute renal failure from myoglobinuria).

Active external cooling (cooling blankets, ice packs).

IV benzodiazepines (lorazepam) for agitation and rigidity.

Specific medical therapy: Bromocriptine (dopamine agonist 2.5–5 mg TDS) or Dantrolene sodium (muscle relaxant 1–2.5 mg/kg IV bolus).

Acute Behavioural Disturbance & Rapid Tranquillisation

Stepwise De-escalation: Verbal engagement, low-stimulus room, offering food/drink.

Oral Medication (First-Line): Oral lorazepam (1–2 mg) OR oral haloperidol (2–5 mg) OR oral olanzapine (5–10 mg) .

Intramuscular Rapid Tranquillisation (Parenteral): Indicated only if oral medication is refused and imminent risk of serious physical injury exists.

IM Lorazepam 1 to 2 mg OR

IM Haloperidol 2 to 5 mg PLUS IM Promethazine 25 to 50 mg (promethazine sedates and prevents acute dystonias).

Warning

Rapid Tranquillisation Safety Rules:

Baseline ECG Mandatory for Haloperidol: Haloperidol prolongs the QTc interval (risk of torsades de pointes). Use IM lorazepam if an ECG cannot be obtained.

NEVER Combine IM Olanzapine and IM Benzodiazepines: Co-administration within 1 hour carries a risk of fatal cardiorespiratory arrest and severe hypotension.

Post-Sedation Monitoring: Monitor respiratory rate, SpO2, pulse, and BP every 15 minutes for 1 hour , then hourly. Ensure flumazenil and resuscitation equipment are accessible.

Other Psychotic Disorders

Delusional disorder: persistent, often well-systematised delusions (for example persecutory, jealous or somatic) for at least 1 month (DSM-5; 3 months in ICD-11), without the other features of schizophrenia, and with relatively preserved functioning. Antipsychotics and psychological approaches are used, although insight is usually poor.

Schizoaffective disorder: symptoms of schizophrenia occur together with a major mood episode (manic or depressive) in the same episode of illness, with psychotic symptoms also present without mood symptoms at times. Management combines an antipsychotic with mood stabilisers or antidepressants as needed.

Substance-induced psychosis (cannabis, stimulants, alcohol withdrawal) and organic causes (delirium, temporal lobe epilepsy, autoimmune encephalitis, steroids) should be excluded in every first episode.

Loading diagram... Antipsychotic Adverse Effect Triage & Emergency Pathway